Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on SCMP’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Sucampo Pharmaceuticals could be a solid choice for investors.
Current Quarter Estimates for SCMP
In the past 30 days, 2 estimates have gone higher for Sucampo Pharmaceuticals while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 33 cents a share 30 days ago, to 44 cents today, a move of 33.3%.
Current Year Estimates for SCMP
Meanwhile, Sucampo Pharmaceuticals’ current year figures are also looking quite promising, with 2 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from $1.03 per share 30 days ago to $1.22 per share today, an increase of 18.5%.
SUCAMPO PHARMAC Price and Consensus
The stock has also started to move higher lately, adding 26.6% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>